Human proof-of-concept study

Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients

A single-arm phase 2 trial in 30 patients with early-stage triple-negative breast cancer.

Cell Metab, 2025. Ligorio F, et al.

Funding and competing interests (as published with the paper): Declaration of interests The authors declare the following competing interests: G.V.B., speaker/advisory board: Novartis, Eli Lilly, Daichi/Astrazeneca, Roche, MSD, and Seagen; G.P., consulting fees: Roche, Bayer, and Astra Zeneca; C.V., consulting fees/advisory board: Novartis, Pfizer, Eli Lilly, Daiichi Sankyo, and Menarini Stemline; C.V., honoraria as speaker: Novartis, Eli Lilly, Istituto Gentili, Accademia Nazionale di Medicina, MSD, Research grant: Roche; F.d.B., consulting fees/advisory board: Roche, EMD Serono, NMS Nerviano Medical Science, Sanofi, MSD, Novartis, Incyte, BMS, Menarini, Astra Zeneca, Pierre Fabre, Mattioli 1885, MCCann Health, Taiho; F.d.B., IQVIA Speaker Bureau: BMS, Healthcare Research & Pharmacoepidemiology, Merck Group, MSD, Pfizer, Servier, Sanofi, Roche, AMGEN, Incyte, Dephaforum, Seagen, Nadirex, BMS, Ambrosetti, and Itanet; and F.d.B., research grant/funding: Novartis, F.Hoffmann-LaRoche Ltd, BMS, Ignyta Inc., Merck Sharp & Dohme Spa, Kymab, Pfizer, Tesaro, MSD, MedImmune LCC, Exelixis Inc., LOXO Oncology Inc., DAICHI SANKIO Dev. Ltd, Basilea Pharmaceutica International AG, Janssen-Cilag International NV, and Merck KGAA. C.V. and F.d.B. are co-inventors of the FMD regimen used in this study. The Italian patent (no. 102019000009954) has been released and was first deposited on June 24(th), 2019, with an extension granted under PCT WO 2020/261131 on June 24(th), 2020. The European patent (no. 207403399), Canadian patent (no. 2144217), and USA patent are pending.

Read the full study

Opens the journal or PubMed page in a new tab. Some journals require a subscription.

Study type
Human clinical trial (phase 2, single-arm, n=30)
Journal
Cell Metab
Published
2025
Authors
Ligorio F, et al.
DOI
10.1016/j.cmet.2024.11.004
PubMed ID
39694040

Summary

Thirty patients with early-stage triple-negative breast cancer, enrolled in the phase 2 BREAKFAST trial, received a severely calorie-restricted 5-day Fasting Mimicking Diet (FMD) every three weeks alongside preoperative chemotherapy. The primary endpoint was the rate of pathologic complete response, with long-term clinical outcomes as secondary endpoints. The authors also ran bulk and single-cell RNA sequencing on tumour samples.

The authors reported pathologic complete response rates that they describe as excellent, together with long-term clinical outcomes, in this group. They reported that in tumours achieving a pathologic complete response, highly glycolytic cancer cells, myeloid cells and pericytes underwent an early reduction in pathways related to glycolysis and pyruvate metabolism. They state that their findings pave the way for larger trials and for validating early changes in tumour glycolysis as a predictor of clinical benefit.

This trial had a single arm and no comparison group, so the response rates cannot be separated from the effect of the chemotherapy given alongside the diet. Thirty patients is a small sample, and the authors describe the work as groundwork for larger trials. The sequencing findings come from the subgroup of tumours that responded, not from the whole group. Participants were patients with early-stage triple-negative breast cancer receiving preoperative chemotherapy, not a general wellness population, and the study does not evaluate Prolon directly.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.